Cargando…
Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer
The forkhead box protein O1 (FOXO1) is considered to be a key tumor suppressor due to its involvement in a broad range of cancer-related functions, including cellular differentiation, apoptosis, cell cycle arrest, and DNA damage. Given that inactivation of FOXO1 has been reported in many types of hu...
Autores principales: | Gheghiani, Lilia, Shang, Shengzhe, Fu, Zheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378169/ https://www.ncbi.nlm.nih.gov/pubmed/32704044 http://dx.doi.org/10.1038/s41598-020-69338-8 |
Ejemplares similares
-
The dark side of PLK1: Implications for cancer and genomic instability
por: Gheghiani, Lilia, et al.
Publicado: (2023) -
The Role of Polo-Like Kinase 1 in Regulating the Forkhead Box Family Transcription Factors
por: Moore, Xavier T. R., et al.
Publicado: (2023) -
Co‐Targeting Plk1 and DNMT3a in Advanced Prostate Cancer
por: Zhang, Zhuangzhuang, et al.
Publicado: (2021) -
Co‐Targeting Plk1 and DNMT3a in Advanced Prostate Cancer
por: Zhang, Zhuangzhuang, et al.
Publicado: (2022) -
FOXO Signaling Pathways as Therapeutic Targets in Cancer
por: Farhan, Mohd, et al.
Publicado: (2017)